Cloning and Expression of C2 and V Domains of ALCAM Protein in E. coli BL21 (DE3)

Dana, Hassan; Mazraeh, Ali; Chalbatani, Ghanbar Mahmoodi; Marmari, Vahid; Mahmoodzadeh, Habibollah; Ghamari, Ali; Moazzen, Fateme; Ebrahimi, Mohammad; Mehmandoost, Narges

doi:10.4172/2327-5073.1000271

Cited by 14 publications

(16 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cancer is accounted for one of the most prevalent diseases with high mortality rates in the world. It is considered one of the major challenges of medical treatment and health 181. For instance, colorectal cancer with more than 1.2 million new cases causes 600 thousand deaths per year and is the fourth cause of deaths worldwide 182.…”

Section: Discussionmentioning

confidence: 99%

<p>Small interfering RNAs (siRNAs) in cancer therapy: a nano-based approach</p>

Chalbatani¹,

Dana²,

Gharagouzloo³

et al. 2019

IJN

Self Cite

187

View full text Add to dashboard Cite

Cancer is one of the most complex diseases that has resulted in multiple genetic disorders and cellular abnormalities. Globally, cancer is the most common health concern disease that is affecting human beings. Great efforts have been made over the past decades in biology with the aim of searching novel and more efficient tools in therapy. Thus, small interfering RNAs (siRNAs) have been considered one of the most noteworthy developments which are able to regulate gene expression following a process known as RNA interference (RNAi). RNAi is a post-transcriptional mechanism that involves the inhibition of gene expression through promoting cleavage on a specific area of a target messenger RNA (mRNA). This technology has shown promising therapeutic results for a good number of diseases, especially in cancer. However, siRNA therapeutics have to face important drawbacks in therapy including stability and successful siRNA delivery in vivo. In this regard, the development of effective siRNA delivery systems has helped addressing these issues by opening novel therapeutic windows which have allowed to build up important advances in Nanomedicine. In this review, we discuss the progress of siRNA therapy as well as its medical application via nanoparticle-mediated delivery for cancer treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

<p>Small interfering RNAs (siRNAs) in cancer therapy: a nano-based approach</p>

Chalbatani¹,

Dana²,

Gharagouzloo³

et al. 2019

IJN

Self Cite

187

View full text Add to dashboard Cite

show abstract

“…Irrespective of socio-economic context, Cancer is the second leading cause of death globally, since it is the third leading cause of death in low- and middle-income countries and the second leading cause of death in high-income countries [1], [2], [3], [4].…”

Section: Introductionmentioning

confidence: 99%

Biological function and molecular mechanism of piRNA in cancer

Chalbatani

Dana

Memari

et al. 2019

Practical Laboratory Medicine

Self Cite

View full text Add to dashboard Cite

Cancer is the second leading cause of death globally. piRNAs, which are a novel type of identified small noncoding RNA (ncRNA), play a crucial role in cancer genomics. In recent years, a relatively large number of studies have demonstrated that several piRNA are aberrantly expressed in various kinds of cancers including gastric cancer, bladder cancer, breast cancer, colorectal cancer and Lung cancer and may probably serve as a novel therapeutic target and biomarker for cancer treatment. The present review summarized current advances in our knowledge of the roles of piRNAs in cancer.

show abstract

“…However, the application of siRNA as an unshielded molecule is compromised and requires the use of an effective delivery strategy [11,12].…”

Section: Introductionmentioning

confidence: 99%